Emmanuelle Nicolas‐Virelizier

Author

Also Known As

E Nicolas-Virelizier, E Nicolas‐Virelizier, E. Nicolas-Virelizier, E. Nicolas‐Virelizier, Emmanuelle Nicolas-Virelizier, Emmanuelle Nicolas-virelizier, Emmanuelle Nicolas‐Virelizier, Frederic Peyrade, Nicolas-Virelizier, E., Nicolas-Virelizier, Emmanuelle

143

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Université Claude Bernard Lyon 1 Assistance Publique – Hôpitaux de Paris Hôpital Saint-Louis Hôpital Lyon Sud

About

Emmanuelle Nicolas‐Virelizier is an author at Centre Léon Bérard specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	1.7K
2	Health Sciences	5	5	175
3	Cellular Therapies	4	4	286
4	Public Health	2	2	343
5	Cell Biology	1	1	35

Emmanuelle Nicolas‐Virelizier

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais, Journal of Clinical Oncology	2014	399
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network Carole Soussain, Sylvain Choquet, Marie Blonski, European Journal of Cancer Neuro-oncologyPrimary Vitreoretinal LymphomaLymphoid NeoplasiaOphthalmologyMedicine	2019	305
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA) H. Ghesquières, Marion Chevrier, Mouna Laadhari, Annals of Oncology	2019	226
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma Matthew J. Maurer, Emmanuel Bachy, Hervé Ghesquières, American Journal of Hematology Lymphoid NeoplasiaCancer EpidemiologyMedicineEpidemiology Of CancerClinical Epidemiology	2016	219
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study Olivier Casasnovas, Réda Bouabdallah, Pauline Brice, The Lancet Oncology Pet-adapted TreatmentLymphoid NeoplasiaMedicinePathologyAdvanced Hodgkin Lymphoma	2019	201
Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma Carrie A. Thompson, Hervé Ghesquières, Matthew J. Maurer, Journal of Clinical Oncology	2014	165
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers Gaëlle Fossard, Florence Broussais, Inês Coelho, Annals of Oncology Lymphoid NeoplasiaCell TherapyTransplantationMedicinePeripheral T-cell Lymphoma	2017	140
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf, Journal of Clinical Oncology	2020	140
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR Souad Assaad, Virginie Avrillon, Marie-Line Fournier, European Journal of Cancer Viral DiagnosticsMedicineCovid-19 PandemicHigh Mortality RateCancer Patients	2020	124
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study Jehan Dupuis, Franck Morschhauser, Hervé Ghesquières, The Lancet Haematology Lymphoid NeoplasiaMedicineImmunodeficienciesPeripheral T-cell LymphomaImmunology	2015	107

Page 1